News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Two-day long National Health Summit highlighted progress under the NHM and called for data-driven and SDG-aligned health system reforms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
